ObjectivesTo assess the visual outcomes in patients who underwent cataract surgery with multifocal intraocular lens (IOL) implantation using a “mix and match” approach.Materials and MethodsTwenty patients (40 eyes) were involved in this prospective, nonrandomized study. Refractive multifocal IOLs (ReZoom NXG1) were implanted in patients’ dominant eyes and diffractive multifocal IOLs (Tecnis ZMA00) were implanted in their non-dominant eyes. Monocular and binocular uncorrected distance, intermediate and near visual acuity (logMAR), and contrast sensitivity levels were measured at 1, 3, and 6 months after cataract surgery. Defocus curves, reading speeds, patient satisfaction, spectacle dependence, and halo and glare symptoms were also evaluated at 6 months after the surgery. Postoperative quality of life was assessed with the Turkish version of National Eye Institute Visual Function Questionnaire-25.ResultsThe study group comprised 8 females and 12 males with a mean age of 69.45±10.76 years (range, 31-86 years). The uncorrected distance and intermediate visual acuity levels were significantly better in the ReZoom-implanted eyes at postoperative 6 months (p=0.026 and p=0.037, respectively). There was no statistically significant difference in uncorrected near visual acuity (p>0.05). There was no statistically significant difference in contrast sensitivity, reading speed, halos, or glare between the groups (p<0.05). Mild glare/halo was reported by 40% of the subjects. The mean patient satisfaction was 95% and all patients were spectacle independent.ConclusionMixing and matching multifocal IOLs in selected cataract patients provides excellent visual outcome, a high level of patient satisfaction, and spectacle independency.
Aim: To compare the effectiveness of photodynamic therapy (PDT) and PDT combined with intravitreal triamcinolone (IVTA) and vascular endothelial growth factor inhibition (anti-VEGF) in age-related macular degeneration (AMD).Materials and methods: Eighty eyes of 80 patients diagnosed with choroidal neovascularization (CNV) caused by AMD were included in the study. PDT was carried out on 40 eyes in group I, and PDT combined with 4 mg IVTA and anti-VEGF (1.25 mg bevacizumab in 20 eyes, 0.3 mg pegaptanib sodium in 20 eyes) was carried out in group II. The primary efficacy endpoint was the mean change from baseline visual acuity at month 12.Results: Mean follow-up was 14.2 ± 2.18 months in group I and 12.45 ± 2.82 months in group II. In group I there was a 2.88 logMAR line decrease and 1.95 logMAR line increase in group II in vision between pretreatment and 12th month measurements (P < 0.05). Mean PDT session was 2.00 in group I and the mean combined treatment session was 1.15 in group II in the 12th month. Conclusion:Combination of IVTA and anti-VEGF with PDT is more effective and safer than PDT monotherapy in the treatment of CNV secondary to AMD. Combination treatment decreases the frequency and number of treatment sessions for an improved visual prognosis.
Amaç: Glokom hastalığı ve yaşa bağlı makula dejeneransı (YBMD) nedeniyle tedavi gören hastalarda, depresif belirtilerin ve anksiyete belirtilerinin varlığının ve yaşam kalitesinin değerlendirilmesidir. Gereç ve Yöntem: 1 Mart 2008-30 Haziran 2008 tarihleri arasında, kliniğimizde takip ve tedavisi yapılan 60 glokom ve 60 YBMD hastası çalışmaya alındı. Kontrol grubu olarak, gözlük muayenesi için gelen ve ek bir şikayeti olmayan 60 hasta dahil edildi. Glokom ve YBMD hastalarının psikiyatrik belirtiler ve yaşam kalitesi üzerine etkilerini değerlendirmek amacıyla, hastalara hastane anksiyete depresyon ölçeği (Hamilton Anksiyete Derecelendirme Ölçeği-HAD), dünya sağlık örgütü yaşam kalitesi ölçeği kısa formu (WHOQOL-BREF TR) verilerek doldurmaları istendi. Çalışma grubunu oluşturan hastaların ve kontrol grubunun yaş, cinsiyet, eğitim durumu kaydedildi. Bulgular: Glokomlu ve YBMD'li hasta gruplarında HADD (Hamilton Anksiyete Derecelendirme Ölçeği-Depresyon) ve HADA (Hamilton Anksiyete Derecelendirme Ölçeği-Anksiyete) alt puanları kontrol grubundan anlamlı düzeyde yüksek bulundu (p<0,05). Glokomlu ve YBMD'li hasta grubu arasında HADD ve HADA puanları arasında anlamlı fark bulunmadı (p>0,05). Glokomlu ve YBMD'li hasta gruplarında WHOQOL-BREF fiziksel, sosyal, çevresel ve psikolojik alanlardaki yaşam kalitesi puanı kontrol grubundan anlamlı olarak düşük bulundu (p<0,05). Glokomlu ve YBMD'li hasta grubu arasında fiziksel, sosyal, çevresel ve psikolojik alanlardaki yaşam kalitesi puanları arasında anlamlı fark bulunmadı (p>0,05). Sonuç: Glokomlu ve YBMD'li hastaların normal populasyona göre yaşam kalitesinin bozulduğu, bu hastaların depresif belirtilerin ve anksiyete belirtilerinin daha fazla bulunduğu gösterilmiştir. Bu nedenle glokomlu ve YBMD'li hastalar gibi kronik seyirli göz hastaların tedavi ve takipleri sürecinde psikiyatrik semptomlar açısından değerlendirilmesi ve desteklenmesinin, hastaların yaşam kalitesi ve prognozunu olumlu yönde etkileyeceği düşüncesindeyiz. (Turk J Ophthalmol 2014; 44: 83-7) Anahtar Kelimeler: Anksiyete, depresyon, glokom, yaşam kalitesi, YBMD Objectives: The aim of the study was to assess the depressive and anxiety symptoms and the quality of life (QofL) in patients treated for glaucoma and age-related macular degeneration (AMD). Materials and Methods: Between March 1 and June 30, 2008, 60 outpatients with glaucoma and AMD were included into the study. As controls, sixty patients with similar sociodemographic features and who applied to the Ophthalmology Clinics with refractive errors only were taken. All patients and controls were applied the 17-item Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), the World Health Organization Quality of Life Assessment-BREF (WHOQOL-BREF) Turkish version. Results: The mean HDRS and HARS scores of the glaucoma and AMD patients were significantly higher than those of the controls (p<0.05). The mean HDRS and HARS scores did not show a significant difference between the patients with glaucoma and AMD (p>0.05). In the glaucoma and...
Aims: To evaluate the optic coherence tomographic (OCT) features in acute central serous chorioretinopathy (ACSC) with time-domain or spectral-domain OCT at Dokuz Eylul University, Department of Ophthalmology, Izmir, Turkey. Subjects and Methods: Clinical data from the Department of Ophthalmology (of Dokuz Eylul University) including fluorescein angiography (FA) and OCT findings of 39 eyes of 34 patients with ACSC were retrospectively analyzed. Eleven eyes (Ntd =11) were examined with time-domain (Stratus OCT 3, Version 4.0) and 28 eyes (Nsd =28) with spectral-domain OCT (Heidelberg HRA2 Spectralis).Results: Of the sample of 34, twenty-four patients (70.6%) were men and 10 women (29.4%). FA demonstrated smokestack type hyperfluorescence in five eyes (12.8%), a round ink blot type hyperfluorescence in 32 eyes (82.1%) and diffuse leakage in two (5.1%) eyes. Twenty-five eyes (64.1%) had only one leakage site, five eyes (12.8%) had two leakage sites and nine eyes (23.1%) had three or more leakage sites. Detachment of the neurosensory retina was detected in 37 eyes (94.9%, 11 eyes with Stratus OCT and 26 eyes with Spectral OCT). Pigment epithelial detachment (PED) was detected in nine eyes (23.1%, one eye with Stratus OCT and eight eyes with Spectral OCT). Protrusion of the RPE layer was detected in 10 eyes (25.6%, all eyes with Spectral OCT). Both fibrinous exudates and bridging between the neurosensory retina and PED was detected with Spectral OCT in four eyes (10.2%). Retinal dipping was detected with Spectral OCT in two eyes (5.1%). Conclusion: Spectral-domain OCT seems to yield more information and depicts RPE layer protrusion, fibrinous exudates and bridging better when compared to conventional time-domain OCT. (S Afr Optom 2012 71(4) [166][167][168][169][170]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.